S7 Estimating the potential impact of residual EDS on the QoL of patients with OSA and, for the first time, their partners, using a time trade-off methodology
Abstract
Introduction and Objectives Excessive daytime sleepiness (EDS) is a common symptom of obstructive sleep apnoea (OSA), persisting in 9% to 22% of patients despite primary airway therapy (residual EDS). EDS can impair work productivity and driving ability, and negatively impact quality of life (QoL) of patients and their partners. This study aimed to elicit QoL values (utilities) from a societal perspective for patients with OSA with residual EDS of varying severity and, for the first time, for the partners of these patients, using a novel time trade-off (TTO) approach. Methods Utility values for health states of varying severities of residual EDS in OSA were elicited using the TTO method in a study conducted with a United Kingdom general public sample (N=110). Four EDS severity health state descriptions were developed from both patient and partner perspectives (no EDS, mild EDS, moderate EDS, severe EDS). During face-to-face interviews, participants were asked to ‘trade off’ time for each EDS health state for a shorter period in full health (0–10 years), first for the patient health states and then for the partner health states. TTO responses were converted to utility values (scale of 0–1, where 0 represents QoL equivalent to death and 1 represents the highest QoL). Results Mean utility scores declined with increasing EDS severity (table 1). In the context of the TTO exercise, participants were prepared to trade a mean of 4.5 life-years (out of a maximum of 10) to avoid the…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.